Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The "Thermo Fisher Scientific Inc.: 360? Company Analysis" report has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive analysis of Thermo Fisher Scientific, covering key details such as key milestones/history, product offerings, technologies, major applications and end-user industries it serves. It includes details of Thermo Fisher Scientific's ownership structure and key management. It also includes company's business segments a ...

Seasoned Executive with Proven Track Record of Value Creation in Life SciencesRADNOR, Pa., July 21, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that it has named Emmanuel Ligner, President and Chief Executive Officer, effective August 18, 2025.Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Direc ...

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.22 per share, reflecting a 2.8% decline year over year, with revenues expected to reach $10.65 billion, a 1% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Laboratory Products and Biopharma Services' at $5.74 billion, a decrease of 0.2% year over year [5]. - 'Revenues- Specialty Diagnostics' are projected to reach $1.14 billion, indicating a 2.5% increase year over year [5]. - 'Revenues- Life Sciences Solutions' are expected to be $2.40 billion, reflecting a 2.1% increase year over year [5]. - 'Revenues- Analytical Instruments' are estimated at $1.79 billion, showing a 0.7% increase year over year [6]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.56 billion, a 0.5% increase from the prior year [6]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.98 billion, reflecting a 0.4% increase year over year [7]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $391.38 million, indicating a 3.3% increase year over year [7]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.69 billion, suggesting a 0.9% increase year over year [8]. Stock Performance - Over the past month, shares of Thermo Fisher have returned +8.3%, outperforming the Zacks S&P 500 composite's +5.4% change [8]. - Currently, TMO holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the second quarter 2025 on Tuesday, August 5, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live ...

Core Viewpoint - INNOVATE Corp. is initiating a series of refinancing transactions aimed at extending the maturities of its debt obligations, which includes exchanges of convertible and senior secured notes, as well as amendments to existing credit agreements [1][2][3]. Debt Refinancing Transactions - The company plans to exchange approximately $48.7 million of its existing 7.5% Convertible Senior Notes due 2026 for about $51.1 million of newly issued 9.5% Convertible Senior Notes due 2027 [2]. - An exchange offer has been launched for $330 million of 8.5% Senior Secured Notes due 2026, offering new 10.5% Senior Secured Notes due 2027 [3][4]. - The refinancing transactions are contingent upon the participation of at least 98% of the outstanding principal amount of the Existing Senior Secured Notes [7]. Agreements in Principle - The company has reached agreements in principle to extend the maturity of its 2020 Revolving Credit Agreement to September 15, 2026 [13]. - An agreement has been made to extend the maturity of the CGIC note to April 2027, with an interest rate of 16% [14]. - The maturity of Spectrum Notes is set to be extended to September 30, 2026, contingent on meeting certain strategic milestones [15]. - The maturity of R2 Technologies' note is proposed to be extended to August 1, 2026, with an interest rate of 12% [16]. Participation and Deadlines - The early participation deadline for the exchange offer is set for July 30, 2025, with the final settlement expected on August 15, 2025 [8]. - Supporting Noteholders, representing approximately 75.3% of the Existing Senior Secured Notes, have agreed to participate in the exchange offer [6].

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planned retirement ...

MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results.Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: https://investors.bio-techne.com/ir ...

Core Insights - Alexandria Real Estate Equities, Inc. (ARE) has signed a 16-year lease for 466,598 rentable square feet (RSF), marking the largest life science lease in its 31-year history [1][10] - The lease is with a long-term multinational pharmaceutical tenant and is part of a build-to-suit research hub located at Campus Point in San Diego [1][10] Group 1: Lease and Development - The new research hub aims for 100% electrification and is targeting LEED Gold Core & Shell and Fitwel certifications, with construction set to begin in 2026 and completion expected in 2028 [3][10] - Campus Point currently has 1.3 million RSF in operation, with a 98.8% occupancy rate, and has potential for future development to expand to approximately 2.6 million RSF, representing a 420% growth since its initial acquisition [5][10] Group 2: Market Position and Strategy - Alexandria has established itself as a leader in life science real estate since its founding in 1994, focusing on creating a unique Megacampus ecosystem that supports a diverse tenant base [4][7] - The company caters to a wide range of high-quality tenants, including multinational pharmaceutical firms and biotechnology companies, although it remains sensitive to changes in the life science and technology sectors [8] Group 3: Future Outlook - The active development and redevelopment pipeline is seen as a positive for long-term growth, but it also presents challenges such as rising construction costs and lease-up concerns amid macroeconomic uncertainty [9]

Investment Rating - The report upgrades the S&P 500 valuation and return forecasts, expecting a rise of 10% to 6900 over the next 12 months, with a forward P/E multiple of 22x [3][4]. Core Insights - The S&P 500 forward P/E of 22x ranks in the 97th percentile since 1980, but is deemed appropriate given the current macroeconomic conditions, including declining interest rates and elevated corporate profitability [3][11][12]. - Earnings growth is projected at 7% for both 2025 and 2026, with EPS estimates of $262 and $280 respectively, although there are two-way risks around these forecasts [6][24]. - The report highlights narrow market breadth, with the median S&P 500 constituent 11% below its high, indicating potential for a momentum reversal in the equity market [30][34]. - Sector allocation recommendations include a mix of secular growth (Software & Services, Media & Entertainment), cyclical (Materials), and defensive (Utilities, Real Estate) industries, with a focus on AI-related technology stocks [41][44]. Summary by Sections Valuation and Earnings Forecasts - The S&P 500 is expected to reach 6900 in 12 months, with return forecasts of +2%, +5%, and +10% over 3, 6, and 12 months respectively [4][47]. - The forward P/E multiple has been increased to 22x, with EPS growth of 7% anticipated for 2025 and 2026 [6][49]. Market Conditions - Current macroeconomic conditions support the elevated P/E multiple, with expectations of earlier Fed easing and lower bond yields [12][16]. - The report notes that investor positioning is neutral, suggesting that current market multiples do not reflect investor exuberance [17][20]. Sector Preferences - There is no clear consensus on sector preferences among clients, but AI-related technology stocks are generally favored despite valuation concerns [41][44]. - The recommendation to invest in Alternative Asset Managers within the Financials sector has been positively received [41]. Market Breadth and Momentum - The S&P 500's recent record high contrasts with the median constituent being significantly below its peak, indicating narrow market breadth [30][34]. - A potential momentum rotation is anticipated, although it is expected to be short-lived rather than indicative of a new long-term trend [40].

Summary of Becton, Dickinson and Company (BDX) and Waters Corporation Conference Call Industry and Companies Involved - **Industry**: Life Sciences and Diagnostics - **Companies**: Waters Corporation and Becton, Dickinson and Company (BDX) Core Points and Arguments 1. **M&A Announcement**: Waters announced a combination with BD's Biosciences and Diagnostic Solutions business via a Reverse Morris Trust, with Waters issuing 39.2% of its shares to BD shareholders and assuming $4 billion in debt [3][6][44]. 2. **Financial Projections**: The combined company is expected to generate pro forma revenue of approximately $6.5 billion and adjusted EBITDA of around $2 billion for 2025 [7][19]. 3. **R&D Investment**: Approximately 10% of product sales will be allocated to R&D to sustain innovation [8][17]. 4. **Employee Count and Headquarters**: The combined entity will have around 16,000 employees and will be headquartered in Milford, Massachusetts [8]. 5. **Market Expansion**: The transaction is expected to double Waters' total addressable market to approximately $40 billion, with a focus on high-volume, regulated applications [9][12]. 6. **Revenue Stability**: Over 70% of the combined revenue is expected to be recurring, enhancing growth stability [10][11]. 7. **Cost and Revenue Synergies**: Expected cost synergies of $200 million by year three and revenue synergies of $290 million by year five [20][41]. 8. **Adjusted Operating Margin**: The combined company aims for an adjusted operating margin of approximately 32% by 2030, with an initial margin of 27% [19][43]. 9. **Strategic Fit**: The combination enhances capabilities in bioseparations, bioanalytical characterization, and multiplex diagnostics, leveraging both companies' strengths [15][36][38]. 10. **Customer Base**: The merger allows for cross-selling opportunities, particularly in flow cytometry and diagnostics, enhancing customer access and service offerings [56][91]. Additional Important Content 1. **Historical Growth**: Both companies have historically grown at mid-single-digit rates, with BD's bioscience and diagnostic solutions business having approximately 80% annual recurring revenue [18][19]. 2. **Innovation Pipeline**: BD's Biosciences is noted for its strong innovation pipeline in flow cytometry and microbiology, while Waters has a robust portfolio in chemistry and analytics [24][26][30]. 3. **Market Positioning**: The combined company is positioned to lead in life sciences tools, with a focus on regulated high-volume settings [47][48]. 4. **Regulatory and Market Access**: The merger is expected to enhance regulatory capabilities and market access for diagnostics, particularly in high-throughput labs [78][92]. 5. **Long-term Value Creation**: The transaction is described as transformational, aiming to create significant long-term value for shareholders, customers, and employees [47][48]. This summary encapsulates the key points from the conference call regarding the merger between Waters Corporation and BD's Biosciences and Diagnostic Solutions, highlighting the strategic, operational, and financial implications of the transaction.